Kiora Pharmaceuticals Files 8-K on Agreements and Equity Sales

Ticker: KPRX · Form: 8-K · Filed: 2026-04-07T07:01:15-04:00

Sentiment: neutral

Topics: definitive-agreement, equity-sale, filing

TL;DR

Kiora Pharma inked new deals and sold stock, check the filings for details.

AI Summary

Kiora Pharmaceuticals Inc. filed an 8-K on April 7, 2026, reporting on the entry into a material definitive agreement and unregistered sales of equity securities. The filing includes exhibits such as the form of security, registration rights, and a press release dated April 3, 2026.

Why It Matters

This filing indicates Kiora Pharmaceuticals is actively engaging in new agreements and issuing equity, which could impact its financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.

Key Players & Entities

FAQ

What type of material definitive agreement did Kiora Pharmaceuticals enter into?

The filing does not specify the exact nature of the material definitive agreement, but it is listed as Item 1.01.

What was the purpose of the unregistered sales of equity securities?

The filing lists 'Unregistered Sales of Equity Securities' as Item 3.02, but the specific purpose or details of these sales are not provided in the summary.

When was the press release mentioned in the exhibits issued?

The press release, referenced as EX-99.1, was issued on April 3, 2026.

What are the key exhibits attached to this 8-K filing?

Key exhibits include forms of securities (EX-4.1, EX-4.2, EX-4.3), security agreements (EX-10.1), registration rights agreements (EX-10.2), and a press release (EX-99.1).

What is Kiora Pharmaceuticals' business address?

Kiora Pharmaceuticals' business address is 169 SAXONY RD. SUITE 212 ENCINITAS CA 92024.

From the Filing

EDGAR Filing Documents for 0001372514-26-000036 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001372514-26-000036 Filing Date 2026-04-07 Accepted 2026-04-07 07:01:15 Documents 18 Period of Report 2026-04-03 Items Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K kprx-20260403.htm iXBRL 8-K 44184 2 EX-4.1 ex41-kioraxpipexformofprex.htm EX-4.1 118228 3 EX-4.2 ex42-kioraxpipexformoftran.htm EX-4.2 255323 4 EX-4.3 ex43-kioraxpipexformoftran.htm EX-4.3 254246 5 EX-10.1 ex101-kioraxpipexsecuritie.htm EX-10.1 328612 6 EX-10.2 ex102-kioraxpipexregistrat.htm EX-10.2 143675 7 EX-99.1 ex991-pressreleasepipeapri.htm EX-99.1 10535 11 KIORA LOGO kprx-20260403_g1.jpg GRAPHIC 28569 Complete submission text file 0001372514-26-000036.txt 1555415 Data Files Seq Description Document Type Size 8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kprx-20260403.xsd EX-101.SCH 1800 9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kprx-20260403_lab.xml EX-101.LAB 22548 10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kprx-20260403_pre.xml EX-101.PRE 13058 21 EXTRACTED XBRL INSTANCE DOCUMENT kprx-20260403_htm.xml XML 2809 Mailing Address 169 SAXONY RD. SUITE 212 ENCINITAS CA 92024 Business Address 169 SAXONY RD. SUITE 212 ENCINITAS CA 92024 858-224-9600 KIORA PHARMACEUTICALS INC (Filer) CIK : 0001372514 (see all company filings) EIN. : 980443284 | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-36672 | Film No.: 26842888 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)

View on Read The Filing